Medmix Ag · SIX:MEDX
Medmix — Corporate Update (October 2023)
7 slides from Medmix's corporate update, Oct 30, 2023
Slide 1: Ad-hoc trading update
Ad-hoc trading update Girts Cimermans, CEO Jennifer Dean, CFO 30 October 2023 Providing innovative solutions to help people live healthier and more confident lives medmix CONFIDENTIAL
Slide 2: Disclaimer and other important notes
Disclaimer and other important notes This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, projections of financial developments, market activities or future performance
Slide 3: Dental market segment
Dental market segment Market continues to grow, but destocking deeper and longer • Previous customer consensus informed clear expectation for restocking in H2 • medmix current order run rate below anticipated improvement • Customers now uncertain about timing of restocking • Emphasis on supply chain
Slide 4: Other medmix market segments
Other medmix market segments Strong growth in Drug Delivery, Surgery, Beauty; Industry recovery on track • Industry segment volumes remain subdued, in line with expectations − medmix increasingly meeting customer demand − Industry recovery plan on track − Full production capacity in Spain by year en
Slide 5: Outlook
Outlook New full-year 2023 guidance1 • Organic revenue growth broadly flat2 • Adjusted EBITDA margin of between 19% and 20%2 Guidance revised due to delays in Dental segment, with above-average influence on results − Dental inventories along value chain reduced to below pre-pandemic levels − Restock
Slide 6: Q&A
Q&A Girts Cimermans, CEO Jennifer Dean, CFO medmix CONFIDENTIAL
Slide 7: Your Investor Relations contact
Your Investor Relations contact James Amoroso Investor Relations, medmix Phone: +41 41 723 73 57 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland medmix CONFIDENTIAL